A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately

Inclusion Criteria: * Subjects in Group 1 must be diagnosed with migraine for at least 1 year prior to study start. Subjects must also have received any dose of flunarizine for the prophylaxis of migraine, for a minimum of 4 weeks prior to the run-in phase. Subjects in Group 2 must be healthy subjects * Weight within 15% of the ideal body weight according to height and frame size * Healthy based on a detailed medical history, physical examination, and clinical laboratory evaluations * Normal ECG at the time of screening * Women of non-child bearing potential or practicing acceptable birth control * Negative pregnancy test within 4 days of run-in phase * Signed informed consent Exclusion Criteria: * History of significant medical disease (e.g., ophthalmologic, cardiovascular, renal, hepatic, gastrointestinal, hematological, endocrine, metabolic, neurologic or psychiatric disease) * Conditions known to be contraindications to the use of flunarizine including obesity, hypotension, a history of depressive illness or pre-existing symptoms of Parkinson's disease or other extrapyramidal disorders * History of an acquired or hereditary neurologic disease, e.g., epilepsy or significant brain trauma * Subjects who are schizophrenic, exhibit bipolar disorder, or have exhibited any psychotic symptoms or have a history of any serious psychiatric disorder, including suicide attempt * Subjects demonstrating significant active physical disease, acute or chronic, within 7 days prior to the start of the study * Active liver disease * Clinically significant abnormal laboratory tests including, but not limited to, an out-of-range screening TSH level, LFT levels greater than or equal to 2 times above the upper limit of normal, a creatinine level above the upper limit of normal * Personal or family history of nephrolithiasis * Allergy to heparin * History of drug allergy or hypersensitivity to sulfonamides (including RWJ-17021-000, topiramate) * Malignancy or history of malignancy within the last 5 years with the exception of treated basal cell carcinoma * Glaucoma * Testing positive for hepatitis B surface antigen, hepatitis C antibody, HIV antibody, and drugs of abuse, including alcohol * History of alcohol or drug abuse * Subjects taking concomitant medications within 14 days prior to Day 1 including iodinated contrast materials that have not been preapproved by the Medical Monitor and Global Clinical Pharmacokinetics Leader * Subjects who have taken medications that are known cytochrome P450 inducers or inhibitors (see Attachment 4) within the 28 days prior to Day 1 * Subjects who have taken prescription medications within 14 days prior to Day 1 (with the exception of chronic thyroid therapy and rescue/abortive medication for migraine headache) or * Over-the-counter medications (including aspirin, vitamins) within 7 days prior to Day 1 or antacids within the 48 hours prior to Day 1 * Use tobacco products during the 3 months prior to screening * Consumption of grapefruit and Seville orange containing products, or herbal medications within the 28 days prior to Day 1 * Drinking alcohol for at least 7 days prior to Day 1 * Subjects who have not limited the consumption of methylxanthine containing products to 2, 8 oz. drinks/day or less within the 24 hours prior to each confinement * Female subjects who are pregnant and/or nursing * Subjects who have received an experimental drug, donated blood, or used an experimental medical device within 30 days prior to screening (also subjects who have been recent participants in a topiramate study, within 2 weeks of screening